ABVD or BEACOPP for Advanced Hodgkin Lymphoma

[1] [Anonymous], 2005, N ENGL J MED

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319

[3] Behringer K, LANCET IN PRESS

[4] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) : 739 - 746

[5] Borchmann P, 2014, 56 ANN M EXP AM SOC

[6] Borchmann P, 2015, 57 ANN M EXP AM SOC

[7] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242

[8] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) : 1478 - 1484

[9] Carde PP, 2012, J CLIN ONCOL S, V30, p510s

[10] ClinicalTrials. gov: A randomized open-label phase 3 trial of A1AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma, RAND OP LAB PHAS 3 T

[1] [Anonymous], 2005, N ENGL J MED

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319

[3] Behringer K, LANCET IN PRESS

[4] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) : 739 - 746

[5] Borchmann P, 2014, 56 ANN M EXP AM SOC

[6] Borchmann P, 2015, 57 ANN M EXP AM SOC

[7] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242

[8] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) : 1478 - 1484

[9] Carde PP, 2012, J CLIN ONCOL S, V30, p510s

[10] ClinicalTrials. gov: A randomized open-label phase 3 trial of A1AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma, RAND OP LAB PHAS 3 T